Log In
Print
BCIQ
Print
Print this Print this
 

retaspimycin HCl (IPI-504)

Also known as: MEDI-561

  Manage Alerts
Collapse Summary General Information
Company Infinity Pharmaceuticals Inc.
DescriptionSmall molecule Hsp90 chaperone inhibitor
Molecular Target Heat shock protein 90 (Hsp90)
Mechanism of ActionHsp90 inhibitor
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase II
Standard IndicationNon-small cell lung cancer (NSCLC)
Indication DetailsSecond- or third-line treatment of non-small cell lung cancer (NSCLC); Treat KRAS mutant non-small cell lung cancer; Treat metastatic non-small cell lung cancer (NSCLC); Treat non-small cell lung cancer (NSCLC); Treat relapsed or refractory non-small cell lung cancer (NSCLC)
Regulatory Designation

Partner


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today